Abstract: A preparation method for a liposome having the ability to stably encapsulate an active ingredient is provided. The preparation method includes providing a mixture and homogenizing the mixture at 300 bar-400 bar to form a liposome suspension. The mixture includes 0.1 wt % of lecithin, 2 wt %-5 wt % of Arabic gum and 63.9125 wt %-97.9 wt % of a solvent. The liposome suspension includes a plurality of liposomes.

Abstract: A preparation method for a liposome having the ability to stably encapsulate an active ingredient is provided. The preparation method includes providing a mixture and homogenizing the mixture at 300 bar-400 bar to form a liposome suspension. The mixture includes 0.1 wt % of lecithin, 2 wt %-5 wt % of Arabic gum and 63.9125 wt %-97.9 wt % of a solvent. The liposome suspension includes a plurality of liposomes.

Abstract: In an aspect, the invention provides methods and uses of PCAT18 for diagnosing, prognosing, and treatment monitoring of prostate cancer (PCa) in a subject. In another aspect, methods of treating PCa in a subject by administering an inhibiting agent of PCAT18 are provided. Uses of PCAT18 in treating PCa in a subject, and pharmaceutical compositions comprising a therapeutic agent effective to reduce the amount of PCAT18 in cancerous prostate cells and a pharmaceutically acceptable carrier, are also provided. The transcript of PCAT18 is a long non-coding RNA (lncRNA), whose expression is significantly altered in biological samples obtained from subjects with PCa or at risk of developing PCa compared to normal individuals. Expression of PCAT18 is specific to prostate tissue and is elevated in both cancerous prostate tissue and blood plasma of subjects with PCa relative to subjects without PCa or patients with other forms of cancer.